A randomised double-blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
Brief Description Of Study
This study is designed to test the hypothesis that ticagrelor monotherapy when compared with clopidogrel monotherapy will reduce the incidence of atherothrombotic ischaemic events, as measured by the composite of CV death, MI, and ischaemic stroke in patients with established PAD. Patients will receive either 90 mg ticagrelor orally bd and clopidogrel placebo in the morning, or 75 mg clopidogrel od (morning) and ticagrelor placebo bd. The patients will be followed for an anticipated minimum of 18 months and up to approximately 36 months.